TTM
$10.57B
YoY change
+8.2%
5Y CAGR
+13.4%
Peak year (2025)
$10.27B
Cumulative gross profit
$67.68B
Gross Profit history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Latest: $10.27B
Gross Profit growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Latest: +8.2%
Gross Profit history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| 2025 | $10.27B | +8.2% | +$777.90M | ||
| 2024 | $9.49B | +10.3% | +$882.60M | ||
| 2023 | $8.61B | +9.6% | +$756.60M | ||
| 2022 | $7.85B | +17.7% | +$1.18B | ||
| 2021 | $6.67B | +22.0% | +$1.20B | ||
| 2020 | $5.47B | +51.3% | +$1.85B | ||
| 2019 | $3.62B | +37.0% | +$977.00M | ||
| 2018 | $2.64B | +19.2% | +$424.52M | ||
| 2017 | $2.21B | +48.4% | +$721.82M | ||
| 2016 | $1.49B | +64.5% | +$584.92M | ||
| 2015 | $906.79M | +74.6% | +$387.37M | ||
| 2014 | $519.43M | -52.0% | −$562.27M | ||
| 2013 | $1.08B | -13.3% | −$165.46M | ||
| 2012 | $1.25B | -6.2% | −$82.96M | ||
| 2011 | $1.33B | +918.2% | +$1.20B | ||
| 2010 | $130.64M | +48.7% | +$42.79M | ||
| 2009 | $87.85M | -45.0% | −$71.97M | ||
| 2008 | $159.82M | -13.7% | −$25.29M | ||
| 2007 | $185.11M | -9.3% | −$19.08M | ||
| 2006 | $204.19M | +35.4% | +$53.39M | ||
| 2005 | $150.79M | +55.3% | +$53.72M | ||
| 2004 | $97.07M | +47.0% | +$31.05M | ||
| 2003 | $66.02M | -50.3% | −$66.79M | ||
| 2002 | $132.80M | +3.9% | +$4.94M | ||
| 2001 | $127.86M | +72.7% | +$53.82M | ||
| 2000 | $74.05M | +13.9% | +$9.04M | ||
| 1999 | $65.00M | +32.9% | +$16.10M | ||
| 1998 | $48.90M | +3.2% | +$1.50M | ||
| 1997 | $47.40M | +187.3% | +$30.90M | ||
| 1996 | $16.50M | -36.0% | −$9.30M | ||
| 1995 | $25.80M | +11.7% | +$2.70M | ||
| 1994 | $23.10M | -27.4% | −$8.70M | ||
| 1993 | $31.80M | +381.8% | +$25.20M | ||
| 1992 | $6.60M | +32.0% | +$1.60M | ||
| 1991 | $5.00M | +117.4% | +$2.70M | ||
| 1990 | $2.30M | — | — |
- 2025$10.27B+8.2%
- 2024$9.49B+10.3%
- 2023$8.61B+9.6%
- 2022$7.85B+17.7%
- 2021$6.67B+22.0%
- 2020$5.47B+51.3%
- 2019$3.62B+37.0%
- 2018$2.64B+19.2%
- 2017$2.21B+48.4%
- 2016$1.49B+64.5%
- 2015$906.79M+74.6%
- 2014$519.43M-52.0%
- 2013$1.08B-13.3%
- 2012$1.25B-6.2%
- 2011$1.33B+918.2%
- 2010$130.64M+48.7%
- 2009$87.85M-45.0%
- 2008$159.82M-13.7%
- 2007$185.11M-9.3%
- 2006$204.19M+35.4%
- 2005$150.79M+55.3%
- 2004$97.07M+47.0%
- 2003$66.02M-50.3%
- 2002$132.80M+3.9%
- 2001$127.86M+72.7%
- 2000$74.05M+13.9%
- 1999$65.00M+32.9%
- 1998$48.90M+3.2%
- 1997$47.40M+187.3%
- 1996$16.50M-36.0%
- 1995$25.80M+11.7%
- 1994$23.10M-27.4%
- 1993$31.80M+381.8%
- 1992$6.60M+32.0%
- 1991$5.00M+117.4%
- 1990$2.30M—
Gross Profit values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current gross profit (TTM) is $10.57B. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported gross profit of $10.27B – grew 8.2% year-over-year.
Vertex Pharmaceuticals gross profit compound annual growth for the 2020–2025 (5 years) window is +13.4%, sustaining 11 straight years of year-over-year growth.
2025 marks the peak gross profit at $10.27B, with the historical low of $2.30M recorded in 1990.
Vertex Pharmaceuticals Gross Profit by Year
Vertex Pharmaceuticals Gross Profit 2025: $10.27B
Vertex Pharmaceuticals posted gross profit of $10.27B in 2025, grew 8.2% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Gross Profit 2024: $9.49B
In 2024, Vertex Pharmaceuticals reported gross profit of $9.49B, grew 10.3% from 2023.
Vertex Pharmaceuticals Gross Profit 2023: $8.61B
Vertex Pharmaceuticals gross profit in 2023 was $8.61B, grew 9.6% from 2022.
Vertex Pharmaceuticals Gross Profit 2022: $7.85B
2022's gross profit for Vertex Pharmaceuticals came in at $7.85B, grew 17.7% from 2021.
Vertex Pharmaceuticals Gross Profit 2021: $6.67B
Vertex Pharmaceuticals gross profit in 2021 was $6.67B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers by Gross Profit
Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation